Sentigen Shareholders Approve Invitrogen Acquisition | GenomeWeb
NEW YORK (GenomeWeb News) - Sentigen Holding today said that its stockholders have approved its planned merger with Invitrogen.
Sentigen said it expects the deal to close “within the next several weeks.”
As GenomeWeb News reported in August, Invitrogen said it planned to acquire Sentigen, which includes its subsidiaries Sentigen Biosciences and Cell & Molecular Technologies for
For around $25.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.